In this issue:
HIV vital signs
NNRTI-sparing regimens for treatment-naive HIV-1
Prenatal exposure to ART and birth defects
Preventing HCV acquisition in injection drug users
High HEV RNA prevalence in blood components
Sofosbuvir-based triple therapy: good economics
Sofosbuvir/ledipasvir effective in HCV GT-1 relapsers
AbbVie-3D promising in established cirrhosis and in HCV GT-1 and no cirrhosis
Moxifloxacin-based regimens for drug-sensitive TB
Decreasing mortality from sepsis Immunoglobulin: no benefit in congenital CMV
Hand sanitisers in classrooms: no reduction in illness absences
Please login below to download this issue (PDF)